本文選題：T細胞免疫球蛋白和黏蛋白域分子　切入點：非小細胞肺癌　出處：《中國癌癥雜志》2017年07期 　論文類型：期刊論文

【摘要】：背景與目的:T細胞免疫球蛋白和黏蛋白域分子3(T cell immunoglobulin and mucin-domaincontaining molecules 3,Tim-3)在免疫調節(jié)中起重要作用,參與多種疾病的發(fā)生、發(fā)展,且與疾病免疫逃逸和疾病臨床預后明顯相關。該研究旨在探討負性共刺激分子Tim-3在非小細胞肺癌(non-small cell lung cancer,NSCLC)浸潤巨噬細胞中的表達及臨床意義。方法:采用免疫組織化學法檢測126例NSCLC患者中Tim-3的表達水平,分析腫瘤組織浸潤巨噬細胞Tim-3的表達水平與臨床病理特征間的關系,并進一步分析Tim-3的表達水平對NSCLC患者預后的影響。結果:Tim-3主要分布于巨噬細胞的細胞質和細胞膜中;Tim-3在腫瘤浸潤巨噬細胞中的表達水平與腫瘤大小、淋巴結轉移及TNM分期均顯著相關(P=0.002、0.045和0.022);Tim-3在腫瘤浸潤巨噬細胞中的表達水平可顯著影響NSCLC患者的生存及預后,在Ⅲ期NSCLC患者中,Tim-3的表達越高,患者總生存期(overall survival,OS)越短(Ⅲ期:χ~2=12.910,P=0.000,中位OS分別為80和32個月)。而且,Tim-3的表達水平與Ⅲ期NSCLC患者的無疾病生存期(disease free survival,DFS)也顯著相關(χ~2=6.135,P=0.013,中位DFS分別為41和24個月),高表達Tim-3的NSCLC患者DFS短。另外,在Ⅲ期NSCLC患者中,Tim-3在淋巴細胞中的表達水平與OS和PFS呈負相關(χ~2=4.737,P=0.030,中位OS分別為80和47個月;χ~2=5.882,P=0.015,中位DFS分別為41和24個月)。結論:Tim-3在腫瘤免疫中起負性調節(jié)作用從而促進免疫逃逸,對患者的生存及預后有不良影響。
[Abstract]:Background & AIM: t cell immunoglobulin and mucin domain molecule 3T cell immunoglobulin and mucin-domaincontaining molecules 3 Tim-3 play an important role in immunomodulation and participate in the occurrence and development of many diseases. The purpose of this study was to investigate the expression and clinical significance of negative costimulatory molecule Tim-3 in infiltrated macrophages of non-small cell lung cancer in non-small cell lung cancer. The expression of Tim-3 in 126 patients with NSCLC was detected by tissue chemistry. To analyze the relationship between the expression level of Tim-3 and clinicopathological features in tumor infiltrating macrophages. The effect of Tim-3 expression level on the prognosis of NSCLC patients was further analyzed. Results the expression of Tim-3-3 was mainly distributed in the cytoplasm of macrophages and in the cell membrane of tumor infiltrating macrophages and the tumor size. Lymph node metastasis and TNM staging were significantly correlated with the expression levels of P0. 002, 0. 045 and 0. 022% Tim-3 in tumor infiltrating macrophages, which significantly affected the survival and prognosis of patients with NSCLC, and the higher the expression of TMT-3 in stage 鈪，

本文編號：1634238